Non-Linear Mixed Effects Models (NLMEM) play an increasing role in drug development process. This work presents various fields of application for NLMEM and improvements in antithrombotic drugs clinical research based on several clinical trials results analysis. A first part emphasis NLMEM interest in pharmacokinetic variability estimation for fondaparinux in unselected subjects and selected subjects with kidney impairment. A second part presents NLMEM usefulness when summarising complex pharmacokinetic - pharmacodynamic response model, with the example of fluindione and acenocoumarol when considering genetic response variability. Finally, an application of NMLEM in drug-drug interaction evaluation is presented with two examples: acenocoumarol-amoxocillin plus clavulanic acid and clopidogrel-fluoxetine interaction
